Myasthenia gravis

Common Name(s)

Myasthenia gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disease. It is characterized by varying degrees of weakness of the skeletal muscles of the body. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expression, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improves after periods of rest.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myasthenia gravis" for support, advocacy or research.

Logo
Muscular Dystrophy Association

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.

http://www.mdausa.org

Last Updated: 8 Mar 2010

View Details
Myasthenia Gravis Foundation of America, Inc.

MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis through research, education, community programs, and advocacy.

http://www.myasthenia.org

Last Updated: 2 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myasthenia gravis" for support, advocacy or research.

Logo
Muscular Dystrophy Association

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.

http://www.mdausa.org

Last Updated: 8 Mar 2010

View Details
Myasthenia Gravis Foundation of America, Inc.

MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis through research, education, community programs, and advocacy.

http://www.myasthenia.org

Last Updated: 2 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myasthenia gravis" returned 727 free, full-text research articles on human participants. First 3 results:

MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.
 

Author(s): Maartje G Huijbers, Wei Zhang, Rinse Klooster, Erik H Niks, Matthew B Friese, Kirsten R Straasheijm, Peter E Thijssen, Hans Vrolijk, Jaap J Plomp, Pauline Vogels, Mario Losen, Silvère M Van der Maarel, Steven J Burden, Jan J Verschuuren

Journal: Proc. Natl. Acad. Sci. U.S.A.. 2013 Dec;110(51):20783-8.

 

Myasthenia gravis (MG) is a severely debilitating autoimmune disease that is due to a decrease in the efficiency of synaptic transmission at neuromuscular synapses. MG is caused by antibodies against postsynaptic proteins, including (i) acetylcholine receptors, the neurotransmitter ...

Last Updated: 18 Dec 2013

Go To URL
Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
 

Author(s): Chengyong Shen, Yisheng Lu, Bin Zhang, Dwight Figueiredo, Jonathan Bean, Jiung Jung, Haitao Wu, Arnab Barik, Dong-Min Yin, Wen-Cheng Xiong, Lin Mei

Journal: J. Clin. Invest.. 2013 Dec;123(12):5190-202.

 

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ). MG is frequently caused by autoantibodies against acetylcholine receptor (AChR) and a kinase critical for NMJ formation, MuSK; however, a proportion of MG patients are double-negative for ...

Last Updated: 2 Dec 2013

Go To URL
Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory.
 

Author(s): Chao Jiang, Ping Liu, Yan Liang, Shaobo Qiu, Wenjing Bao, Jingsheng Zhang

Journal: J Tradit Chin Med. 2013 Aug;33(4):444-8.

 

To study the use of Jianjining in the treatment of myasthenia gravis (MG) patients with a deficiency of both spleen and kidney via the theory on the combination of disease with syndrome.

Last Updated: 5 Nov 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myasthenia gravis" returned 44 free, full-text review articles on human participants. First 3 results:

Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles.
 

Author(s): Alessandro Serra, Robert L Ruff, Richard John Leigh

Journal: Ann. N. Y. Acad. Sci.. 2012 Dec;1275():129-35.

 

An appropriate density of acetylcholine receptors (AChRs) and Na(+) channels (NaChs) in the normal neuromuscular junction (NMJ) determines the magnitude of safety factor (SF) that guarantees fidelity of neuromuscular transmission. In myasthenia gravis (MG), an overall simplification ...

Last Updated: 2 Jan 2013

Go To URL
Biomarker development for myasthenia gravis.
 

Author(s): Henry J Kaminski, Linda L Kusner, Gil I Wolfe, Inmaculada Aban, Greg Minisman, Robin Conwit, Gary Cutter

Journal: Ann. N. Y. Acad. Sci.. 2012 Dec;1275():101-6.

 

Biomarkers are defined as characteristics (e.g., proteins, RNA, single nucleotide polymorphisms, imaging) that are objectively measured and evaluated as indicators of pathogenic processes or pharmacologic responses to therapeutic intervention. Biomarkers are important in clinical ...

Last Updated: 2 Jan 2013

Go To URL
Functional defect in regulatory T cells in myasthenia gravis.
 

Author(s): Muthusamy Thiruppathi, Julie Rowin, Qin Li Jiang, Jian Rong Sheng, Bellur S Prabhakar, Matthew N Meriggioli

Journal: Ann. N. Y. Acad. Sci.. 2012 Dec;1274():68-76.

 

Forkhead box P3 (FOXP3) is a transcription factor necessary for the function of regulatory T cells (T(reg) cells). T(reg) cells maintain immune homeostasis and self-tolerance and play an important role in the prevention of autoimmune disease. Here, we discuss the role of T(reg) cells ...

Last Updated: 20 Dec 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Exercise for Stable Myasthenia Gravis
 

Status: Recruiting

Condition Summary: Myasthenia Gravis

 

Last Updated: 19 Aug 2013

Go to URL
Phase II Trial of Rituximab In Myasthenia Gravis
 

Status: Not yet recruiting

Condition Summary: Myasthenia Gravis

 

Last Updated: 15 Apr 2014

Go to URL
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
 

Status: Recruiting

Condition Summary: Myasthenia Gravis

 

Last Updated: 4 Feb 2014

Go to URL